Nonalcoholic Fatty Liver Disease

TABLE 5

Euglycemic clamp data in the three study groups

NAFLD patients Type 2 diabetic patients Control subjects
n 30 10 10
Steady-state glucose (mmol/l) 5.0 ± 0.3 (4.4–5.6) 5.1 ± 0.2 (4.9–5.5) 4.9 ± 0.2 (4.6–5.2)
Steady-state insulin (pmol/l) 667 ± 103 (487–940) 722 ± 122 (581–918)* 590 ± 55 (531–696)
Glucose infusion rate (μmol · kg−1 · min−1) 19.5 ± 5.7 (10.4–33.6)* 16.2 ± 4.0 (10.8–23.2)* 37.2 ± 9.4 (24.7–58.4)
Glucose disposal rate (μmol · kg−1 · min−1) 18.4 ± 5.9 (8.2–31.6)* 18.0 ± 4.0 (13.2–26.1)* 36.8 ± 7.6 (26.2–54.7)
Fasting FFAs (mmol/l) 0.67 ± 0.27 (0.26–1.30)* 0.55 ± 0.11 (0.44–0.81)* 0.37 ± 0.12 (0.23–0.61)
End-of-clamp FFAs (mmol/l) 0.21 ± 0.14 (0.05–0.55)* 0.13 ± 0.05 (0.06–0.20)* 0.06 ± 0.02 (0.03–0.10)
  • Data are means ± SD (range).

  • *

    * P < 0.001 vs. control subjects.

This Article

  1. Diabetes vol. 50 no. 8 1844-1850